key: cord-0848343-znfpa8lk authors: Kaltenbach, H.-M.; Rudolf, F.; Linnik, J.; Deichmann, J.; Ruf, T.; Altamura, R.; Kapetanovic, E.; Mason, D.; Wagner, B.; Goetz, T.; Mundorff, L.; Stoll-Rudin, K.; Krebs, C.; Renz, T.; Hochueli, T.; Haymoz, S.; Hosch, M.; Periat, N.; Richert, M.; Sesia, S.; Paris, D.; Quinto, C. B.; Probst-Hensch, N.; Niederhauser, C.; Reddy, S.; Nickel, B.; Savic, M. title: Initial characterisation of ELISA assays and the immune response of the clinically correlated SARS-CoV-2 biobank SERO-BL-COVID-19 collected during the pandemic onset in Switzerland date: 2020-07-07 journal: nan DOI: 10.1101/2020.07.05.20145888 sha: 029d2eea5a84a76b3cf8b80aef795b2b4116922c doc_id: 848343 cord_uid: znfpa8lk Background: To accurately measure seroprevalance in the population, boththe expected immune response as well as the assay performances have to be well characterised. Here, we describe the collection and initial characterisation of a blood and saliva biobank obtained after the initial peak of the SARS-CoV-2 pandemic in Switzerland. Methods: Two laboratory ELISA assays measuring IgA & IgG (Euroimmun), and IgM & IgG (Epitope Diagnostics) were used to characterise the biobank collected from 349 re- and convalescent patients from the canton of Basel-Landschaft. Findings: The antibody response in terms of recognized epitopes is diverse, especially in oligosymptomatic patients, while the average strength of the antibody response of the population does correlate with the severity of the disease at each time point. Interpretation: The diverse immune response presents a challenge when conducting epidemiological studies as the used assays only detect 90% of the oligosymptomatic cases. This problem cannot be rectified by using more sensitive assays or lower cut-offs as they concomitantly reduce specificity. Funding Funding was obtained from the Amt fur Gesundheit of the canton Basel-Landschaft, Switzerland. Venous blood was taken by puncturing a disinfected cubital or similar 78 area using a BD safety-lock system into a vacutainer. In total, 10-12 mL 79 each for EDTA-blood serum was taken. The blood collection was performed 80 by a medical assistant or nurse. After blood collection, the samples were 81 either transferred to the diagnostic lab or directly processed on site in the 82 make-shift laboratory. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.05.20145888 doi: medRxiv preprint Saliva was collected non-invasively using the dedicated Salivette tubes 85 (Sarstedt Cat. # 51.1534). In short, the participant delivered saliva into an 86 adsorbent filter, which was then placed by the participant in the Salivette 87 tube. After handover to the medical staff, the saliva was centrifuged on site 88 at 4 • C using 1,000× g for 2 min to remove cells and debris. The tube was 89 then rapidly frozen using a salted ice-water bath and stored at −20 • C before 90 transporting to the lab on dry ice and storage at −80 • C until further use. inactivated FBS supplemented with 10% DMSO) and aliquoted into two 1.5 106 mL cryogenic tubes (Nalgene System, Thermo Scientific, Cat. # 5000-1020). The cryogenic tubes were put into freezing containers Mr.Frosty TM (Thermo 108 Scientific, Cat. # 5100-0001) and the containers were immediately placed 109 6 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2020. into an −80 • C freezer for 24 hrs, and then transferred into a liquid nitrogen tank. Additionally, the tests were imaged using a Nikon D5000 camera. To enable a quantitative comparison between ELISA experiments, we 132 calculated fold changes in OD relative to the assay-and run-specific cut-off 133 7 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2020. . The goal of our study design was to collect a representative cohort of All RT-PCR-tested individuals were eligible for participation except when 168 they were <18 years of age, had a severely compromised immune system, 169 were hospitalized at the time of sample collection, or were deceased. From 170 these, 349 positive individuals committed to participating in the study, 171 and 111 negative individuals were randomly selected. We aimed for suffi-172 cient sample size for two positive cohorts: an 'acute' cohort with diagnosed 173 COVID-19 up to 12 days before study entry, and a 'convalescent' cohort 174 with more than 12 days between positive diagnosis and study entry. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.05.20145888 doi: medRxiv preprint examined in a make-shift field hospital erected next to the building to mini- Table 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. Last row shows distribution of ages 15+ in canton of Basel-Land in 2019 for reference. * Note that our study cohort does not include minors with less than 18 years of age. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.05.20145888 doi: medRxiv preprint period blood donors, and (ii) our negative cohort. These cohorts should 197 strengthen the specificity calculations, but also help to address cross-reactivity 198 to viruses currently in circulation. However, the PCR test is prone to false 199 negatives, and we therefore expect to find a small number of incorrectly Table 3 . We find specificities of the IgG-based 220 assays of about 98%-99%, while IgA shows considerably lower and IgM con- CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.05.20145888 doi: medRxiv preprint The IgG-and IgA-based assays show overall sensitivities above 87%, 227 while the sensitivity of IgM is extremely low at slightly above 50%. How- is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.05.20145888 doi: medRxiv preprint We performed the same analysis stratified by three levels of disease 244 severity-'no restriction', 'help needed', and 'bedridden'-and combined 245 these levels with two levels for days after onset of symptoms: short (≤ 21 246 days) or long (> 21 days). The resulting sensitivities and specificities and 247 their 95% confidence intervals are given in Table 5 . As expected, sensitivities 248 also increase with severity of symptoms for both less and more than three is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.05.20145888 doi: medRxiv preprint Intra-assay variability was determined by calculating the mean, stan- Figure 11) . Additionally, 275 we found that the IgG, but not the IgM, assay from EDI is sensitive to 276 haemolysis (Supplementary Figure 12) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.05.20145888 doi: medRxiv preprint seems to be more prevalent at later time points (Figure 2A) . However, neither IgG response is significantly different depending on the severity of the 306 disease. The IgA response against the spike protein is produced rapidly in 307 the absence of an IgG response but subsides at later time points when the 308 IgG response becomes dominant. Since only 11 cases remained in the hospital at the time of recruitment, this 319 bias is likely small. Overall, we consider the largely representative sample a 320 strength of our biobank, as it allows us to estimate the kinetics of serocon-321 version and assay performance characteristics on samples closely resembling 322 those expected in population-wide studies for sero-prevalence. 323 We find that both specificity and sensitivity are below the manufacturers 324 specifications for all four tests, and observe similar sensitivities only for our 325 'bedridden' group. This indicates that characterizations by the manufac-326 turers are likely based on 'severe' cohorts, which limits their applicability 327 and impairs planning of sero-prevalence studies. We also find that the IgA 328 and IgG assays allow for quantification within a relatively narrow range: the 329 25 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 7, 2020. The average strength of the antibody response, as measured by the ra- CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.05.20145888 doi: medRxiv preprint This study was sponsored by Jürg Sommer, head of the "Amt für Gesund- CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.05.20145888 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 7, 2020. . https://doi.org/10.1101/2020.07.05.20145888 doi: medRxiv preprint A systematic review of antibody me-367 diated immunity to coronaviruses: antibody kinetics tection, and association of antibody responses with severity of disease Journal of clinical virology: the 372 official publication of the Pan American Society for A serological assay to detect SARS-CoV-2 381 seroconversion in humans Diagnosis 383 of severe acute respiratory syndrome (SARS) by detection of SARS 384 coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-385 linked immunosorbent assay Sensitivity in detection of antibodies to nucleocapsid and spike proteins 390 of severe acute respiratory syndrome coronavirus 2 in patients with 391 coronavirus disease Neutralizing antibody responses to SARS-CoV-2 COVID-19 recovered patient cohort and their implications SARS-CoV-2 neutralizing antibodies and protection from disease in a 398 small animal model Emerging 403 infectious diseases Kinetics of SARS-CoV-2 specific IgM IgG responses in COVID-19 patients Antibody responses to SARS-CoV-2 in patients with COVID-19 Delayed specific IgM antibody responses observed 413 among COVID-19 patients with severe progression, Emerging Microbes 414 & Infections Rapid generation of neutralizing antibody responses 418 in COVID-19 patients Viro-421 logical assessment of hospitalized patients with COVID-2019 FDA, Analytical validation and points for discussion How innate immune mechanisms contribute to 425 antibody-enhanced viral infections Characteristics of patients with coronavirus 429 disease (COVID-19) confirmed using an IgM-IgG antibody test R: A Language and Environment for Statistical Foundation for Statistical Computing PropCIs: Various Confidence Interval Methods for Propor-434 tions Vari-436 ation in false-negative rate of reverse transcriptase polymerase chain 437 reaction-based SARS-CoV-2 tests by time since exposure False-negative of RT-PCR and 440 prolonged nucleic acid conversion in COVID-19: rather than recurrence